Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

How one antibiotic dose can reshape your gut microbiome for years

Long-term registry-linked analysis of nearly 15,000 adults shows that antibiotic use is associated with persistent changes in gut microbiome diversity and composition for up to 4–8 years. These effects vary by antibiotic class, with clindamycin, fluoroquinolones, and flucloxacillin showing the strongest and most sustained associations.

17 Mar 2026

Researchers show how smartwatches can help identify insulin resistance

Researchers developed a scalable framework that predicts insulin resistance using wearable-device signals, routine blood biomarkers, and demographic data, with stronger performance when these data streams were combined. The study also introduced an AI agent to explain insulin resistance risk, interpret results, and support earlier metabolic risk screening.

17 Mar 2026

Expert consensus validates UDFF for noninvasive fatty liver assessment

As the global burden of obesity, type 2 diabetes, and metabolic syndrome continues to rise, fatty liver disease has become one of the most prevalent chronic liver conditions worldwide. Its progressive forms, including metabolic dysfunction‐associated steatohepatitis (MASH), cirrhosis, and hepatocellular carcinoma, now represent a major public health challenge.

17 Mar 2026

Patients who stop GLP-1 drugs often restart or try alternatives

The study highlights that after stopping GLP-1 medications, many patients resume treatment or try alternatives, influencing weight management strategies.

17 Mar 2026

New polygenic risk scores improve prediction of metabolic disease outcomes

Type 2 diabetes (T2D) and obesity are metabolic conditions with many causes, including overlapping and distinct genetic features.

16 Mar 2026

Why do some people respond better to GLP-1 drugs? Gut microbiome may hold clues

A review in the Canadian Journal of Physiology and Pharmacology examines emerging evidence linking glucagon-like peptide-1 receptor agonists (GLP-1 RAs), the gut microbiome, and obesity treatment outcomes. The authors conclude that microbiome changes seen during therapy are most likely driven by diet, behavior, and weight loss, although microbial profiling may eventually help predict patient responses.

15 Mar 2026

Updated guideline emphasizes earlier treatment for high cholesterol

The American College of Cardiology (ACC), the American Heart Association and nine other leading medical associations, today issued an updated guideline for the management of dyslipidemia-abnormal levels of one or more types of lipids or lipoproteins in the blood, including cholesterol and triglycerides.

13 Mar 2026

New RNA therapy enhances the heart's ability to repair itself after injury

After a heart attack, cardiologists can reopen blocked vessels and restore blood flow, but the muscle cells that died will never be replaced.

13 Mar 2026

Cambridge’s LED breakthrough reinvents drug synthesis

Scientists at the University of Cambridge have developed a new way to alter complex drug molecules using light rather than toxic chemicals – a discovery that could accelerate and improve how medicines are designed and made.

13 Mar 2026

Real-world study shows modest weight regain after GLP-1 discontinuation

As the use of injectable GLP-1 drugs continues to rise, questions persist about what happens after patients stop taking them in real-world settings.

12 Mar 2026

Can eating almonds reduce inflammation in obesity?

Adding almonds to the diet of adults with obesity enhances inflammatory cytokine profiles and diet quality, highlighting a simple anti-inflammatory strategy.

12 Mar 2026

New digital shield against metabolic disease in youth psychosis

A new clinic-ready web-based risk prediction tool called PsyMetRiC is now available to forecast the risk of young people with psychosis developing cardiometabolic disorders such as obesity, metabolic syndrome and diabetes.

12 Mar 2026

Some antibiotics alter gut microbiome composition for up to eight years

Antibiotic treatments can affect the composition of the community of bacteria living in the gut, known as the gut microbiome, for a long time.

11 Mar 2026

Low testosterone and high fructose intake can worsen fatty liver disease

Low testosterone in itself can cause a variety of health problems, but the addition of a poor diet can exacerbate certain conditions. Metabolic dysfunction-associated steatotic liver disease (MASLD) is one example that approximately 40% of adult men worldwide currently suffer from and has become a global problem.

11 Mar 2026

Wegovy linked to higher risk of eye stroke and vision loss

Wegovy, a GLP-1 agonist for weight loss, may carry the highest risk of 'eye stroke' (ischemic optic neuropathy) and sudden sight loss of the semaglutide drugs, finds an analysis of unintended side effect reports published in the British Journal of Ophthalmology.

10 Mar 2026

Hormone asprosin linked to long-term weight changes after menopause

Researchers at the University of California, Irvine Joe C. Wen School of Population & Public Health have identified how the hormone asprosin influences long-term weight change among postmenopausal women in the United States.

10 Mar 2026

Postbiotics may help treat PCOS by restoring microbiome balance

Emerging studies suggest postbiotics could aid PCOS management by restoring gut microbiome balance and enhancing insulin sensitivity and hormonal regulation.

10 Mar 2026

Alcohol intake linked to lower micronutrient intake in men with type 2 diabetes

Researchers analyzed 1,565 Japanese outpatients with type 2 diabetes and found that higher alcohol consumption was associated with lower intake of several micronutrients, particularly potassium, calcium, and vitamins A and C, in younger men. The study also linked alcohol intake to a savory dietary pattern rich in rice, meat, fish, and seasonings, highlighting age- and sex-specific nutritional risks.

9 Mar 2026

Women face higher liver fibrosis risk from cardiometabolic factors than men

Women with certain cardiometabolic risk factors, including type 2 diabetes and high waist circumference, face a greater increase in risk for liver fibrosis than men with the same risk factors.

9 Mar 2026

Could GLP-1 drugs help curb addiction? Large veteran study points to potential benefit

A large cohort study of more than 600,000 US veterans with type 2 diabetes found that initiating GLP-1 receptor agonists was associated with lower risks of developing substance use disorders compared with SGLT-2 inhibitors. Among veterans with existing substance use disorders, GLP-1 receptor agonist use was also linked to fewer overdose events, hospitalizations, and suicide-related outcomes.

8 Mar 2026